[Research progress of biologics in the treatment of chronic rhinosinusitis]

Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal airways and paranasal sinuses. The condition is defined by more than 12 weeks of nasal obstruction, nasal discharge, facial pain/pressure, and reduced/lost smell. CRS is commonly further classified into 2 subsets based on its clinical phenotype: those with polyps (CRSwNP) and those without (CRSsNP). The incidence of CRS increases year by year. Due to its persistent, intractable and easy to relapse, CRS seriously affects patient's daily work and life. In addition, CRS also increases the patient's financial burden. However, the etiology and pathogenesis of CRS is complex, which limited the clinical treatment in CRS. This review summarizes the latest advances in inflammatory pathways and biologics therapies of CRS based on the latest research results.